false
0001173313
0001173313
2026-08-03
2026-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 3, 2026
ABVC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-40700 |
|
26-0014658 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
44370 Old Warm Springs Blvd.
Fremont, CA |
|
94538 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number including area
code: (510) 668-0881
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
|
Trading Symbol |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
ABVC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On August 3, 2026, ABVC BioPharma, Inc. (the “Company”)
determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the “Distribution”),
which had been scheduled to occur on August 3, 2026. The postponement will provide the Company with additional time to complete certain
administrative, regulatory and tax-related matters necessary to effect the Distribution.
The Company is coordinating with The Nasdaq Stock
Market LLC, The Depository Trust Company and the Company’s transfer agent regarding the revised distribution mechanics and the establishment
of updated dates for the Distribution.
The previously announced record date remains unchanged,
and the distribution ratio will remain 0.169464 ordinary shares of BioKey (Cayman), Inc. for each share of the Company’s common
stock held as of the record date. The previously announced ex-dividend date will no longer apply and will be revised in connection with
the establishment of a new distribution date.
The Company intends to announce the revised distribution
date and corresponding ex-dividend date after such dates have been finalized and the remaining administrative, regulatory, and tax-related
matters have been completed.
SIGNATURE
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ABVC BioPharma, Inc. |
| |
|
|
| August 3, 2026 |
By: |
/s/ Uttam Patil |
| |
|
Uttam Patil |
| |
|
Chief Executive Officer |
